🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

David Einhorn’s BIO Holdings & Trades

First Buy
Q3 2026
Duration Held
1 Quarters
Largest Add
Q3 2026
+103,990 Shares
Current Position
103,990 Shares
$39.28 M Value

David Einhorn's BIO Position Overview

David Einhorn (via Dme Capital Management, Lp) currently holds 103,990 shares of Bio-Rad Laboratories, Inc. (BIO) worth $39.28 M, representing 1.11% of the portfolio. First purchased in 2026-Q3, this recently established position has been held for 1 quarters.

Based on recent 13F filings, David Einhorn has initiated a new position in BIO, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

David Einhorn's Bio-Rad Laboratories (BIO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Bio-Rad Laboratories (BIO) Trades by David Einhorn

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +103,990 New Buy 103,990 $377.71

David Einhorn's Bio-Rad Laboratories Investment FAQs

David Einhorn first purchased Bio-Rad Laboratories, Inc. (BIO) in Q3 2026, acquiring 103,990 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

David Einhorn has held Bio-Rad Laboratories, Inc. (BIO) for 1 quarters since Q3 2026.

David Einhorn's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q3 2026, adding 103,990 shares worth $39.28 M.

According to the latest 13F filing for Q3 2026, David Einhorn's firm, Dme Capital Management, Lp, owns 103,990 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $39.28 M.

As of the Q3 2026 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 1.11% of David Einhorn's publicly disclosed stock portfolio, making it one of their key holdings.

David Einhorn's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 103,990 shares, as reported at the end of Q3 2026.